Lista de obras -

"Pseudo-progression" in advanced thyroid cancer in response to kinase inhibitor therapy.

artículo científico publicado en 2017

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer

artículo científico publicado en 2015

A One-Step Method for Protein Estimation in Biological Samples: Nitration of Tyrosine in Nitric Acid

artículo científico publicado en 1999

A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer

scientific article published on 01 November 2019

A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.

artículo científico publicado en 2014

A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer

artículo científico publicado en 2012

A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors

artículo científico publicado en 2007

A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261

artículo científico publicado en 2012

A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma

artículo científico publicado en 2019

Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets

artículo científico publicado en 2014

American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer

article

American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invas

artículo científico publicado en 2017

An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer

artículo científico publicado en 2020

Annatto constituent cis-bixin has selective antimyeloma effects mediated by oxidative stress and associated with inhibition of thioredoxin and thioredoxin reductase

artículo científico publicado en 2010

Antitumor Activity of VB-111, a Novel Antiangiogenic Virotherapeutic, in Thyroid Cancer Xenograft Mouse Models

artículo científico publicado en 2011

Bone metastases in thyroid cancer

artículo científico publicado en 2020

Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress

artículo científico publicado en 2006

Characterization of Caspase Processing and Activation in HL-60 Cell Cytosol Under Cell-free Conditions

artículo científico publicado en 1999

Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol.

artículo científico publicado en 2000

Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma

artículo científico publicado en 2020

Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group

artículo científico publicado en 2015

Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration ⬇️

artículo científico publicado el 15 de agosto de 1997

Development and characterization of a differentiated thyroid cancer cell line resistant to VEGFR-targeted kinase inhibitors

artículo científico publicado en 2014

Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers

artículo científico publicado en 2012

Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers.

artículo científico publicado en 2012

Diagnosis and Management of Anaplastic Thyroid Cancer

scientific article published on 01 March 2019

Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial

artículo científico publicado en 2013

Effect of P-glycoprotein on flavopiridol sensitivity

artículo científico publicado en 2001

Effect of thyroid hormone suppression on control of advanced well-differentiated thyroid cancer.

artículo científico publicado en 2017

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

artículo científico publicado en 2010

Emergence of resistant clones in medullary thyroid cancer may not be rescued by subsequent salvage highly selective RET-inhibitor therapy

scientific article published on 14 July 2020

Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches

artículo científico publicado en 2011

Enhanced Survival in Locoregionally Confined Anaplastic Thyroid Carcinoma: A Single-Institution Experience Using Aggressive Multimodal Therapy ⬇️

artículo científico publicado el 16 de diciembre de 2010

European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium.

artículo científico publicado en 2019

Evolving molecularly targeted therapies for advanced-stage thyroid cancers

artículo científico publicado en 2016

Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study

artículo científico publicado en 2017

External beam radiation therapy for advanced/unresectable malignant paraganglioma and pheochromocytoma.

artículo científico publicado en 2017

Flavopiridol binds to duplex DNA.

artículo científico publicado en 2000

Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergy

artículo científico publicado en 2006

Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points.

artículo científico publicado en 2006

Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells

artículo científico publicado en 1996

Foundation OneTM Genomic Interrogation of Thyroid Cancers in Patients with Metastatic Disease Requiring Systemic Therapy

scientific article published on 18 May 2020

Individualization of therapies for patients with advanced differentiated thyroid cancers

scientific article published on 01 September 2012

Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity.

artículo científico publicado en 2007

Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma

artículo científico publicado en 2014

Leveraging the immune system to treat advanced thyroid cancers

artículo científico publicado en 2016

Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer.

artículo científico publicado en 2001

Management of treatment-related toxicities in advanced medullary thyroid cancer.

artículo científico publicado en 2018

Mutated BRAF and personalised medicine in differentiated thyroid cancer.

artículo científico publicado en 2016

New drugs for medullary thyroid cancer: new promises?

artículo científico publicado en 2016

OPTIMIZING LENVATINIB THERAPY IN PATIENTS WITH METASTATIC RADIOACTIVE IODINE-RESISTANT DIFFERENTIATED THYROID CANCERS.

artículo científico publicado en 2017

Operative intervention for recurrent adrenocortical cancer

artículo científico

Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer

artículo científico publicado en 2013

Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies.

scientific article published on 26 July 2013

Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points.

artículo científico publicado en 2005

Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias

artículo científico publicado en 2005

Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma.

artículo científico publicado en 2017

Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib.

artículo científico publicado en 2010

Promises and Perils of Molecularly Targeted Therapeutics in Anaplastic Thyroid Cancer

artículo científico publicado en 2016

Prosurvival function of the granulin-epithelin precursor is important in tumor progression and chemoresponse

artículo científico publicado en 2007

Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer

artículo científico publicado en 2017

Salvage Therapy With Multikinase Inhibitors and Immunotherapy in Advanced Adrenal Cortical Carcinoma

artículo científico publicado en 2020

Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity

artículo científico publicado en 2006

Surgical Treatment of Malignant Pheochromocytoma and Paraganglioma: Retrospective Case Series

artículo científico publicado en 2017

Surgical resection of synchronously metastatic adrenocortical cancer

artículo científico

Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer

artículo científico publicado en 2017

Systemic therapeutic approaches to advanced thyroid cancers.

artículo científico publicado en 2012

Taking stock of therapeutic progress in metastatic radioactive iodine-refractory differentiated thyroid cancer: what's next?

artículo científico publicado en 2013

The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux

artículo científico publicado en 2001

The Nitric Acid Method for Protein Estimation in Biological Samples

The anticancer agent chaetocin is a competitive substrate and inhibitor of thioredoxin reductase

artículo científico publicado en 2009

Toward improved outcomes in patients with anaplastic thyroid cancer.

artículo científico publicado en 2012

Toward predictive biomarkers of response to kinase inhibitor therapies in differentiated thyroid cancer

artículo científico publicado en 2017

Toward predictive biomarkers of response to kinase inhibitor therapies in differentiated thyroid cancer

artículo científico publicado en 2017

Treating advanced radioresistant differentiated thyroid cancer

artículo científico publicado en 2012

Lista de obras de

"Pseudo-progression" in advanced thyroid cancer in response to kinase inhibitor therapy.

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer

A One-Step Method for Protein Estimation in Biological Samples: Nitration of Tyrosine in Nitric Acid

A Phase 2 Study of Pembrolizumab Combined with Chemoradiotherapy as Initial Treatment for Anaplastic Thyroid Cancer

A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H.

A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer

A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors

A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261

A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma

Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets

American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer

American Thyroid Association Guidelines on the Management of Thyroid Nodules and Differentiated Thyroid Cancer Task Force Review and Recommendation on the Proposed Renaming of Encapsulated Follicular Variant Papillary Thyroid Carcinoma Without Invas

An International Phase 2 Study of Pazopanib in Progressive and Metastatic Thyroglobulin Antibody Negative Radioactive Iodine Refractory Differentiated Thyroid Cancer

Annatto constituent cis-bixin has selective antimyeloma effects mediated by oxidative stress and associated with inhibition of thioredoxin and thioredoxin reductase

Antitumor Activity of VB-111, a Novel Antiangiogenic Virotherapeutic, in Thyroid Cancer Xenograft Mouse Models

Bone metastases in thyroid cancer

Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress

Characterization of Caspase Processing and Activation in HL-60 Cell Cytosol Under Cell-free Conditions

Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol.

Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinoma

Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group

Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration ⬇️

Development and characterization of a differentiated thyroid cancer cell line resistant to VEGFR-targeted kinase inhibitors

Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers

Development of a multidisciplinary, multicampus subspecialty practice in endocrine cancers.

Diagnosis and Management of Anaplastic Thyroid Cancer

Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial

Effect of P-glycoprotein on flavopiridol sensitivity

Effect of thyroid hormone suppression on control of advanced well-differentiated thyroid cancer.

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

Emergence of resistant clones in medullary thyroid cancer may not be rescued by subsequent salvage highly selective RET-inhibitor therapy

Emerging therapeutics for advanced thyroid malignancies: rationale and targeted approaches

Enhanced Survival in Locoregionally Confined Anaplastic Thyroid Carcinoma: A Single-Institution Experience Using Aggressive Multimodal Therapy ⬇️

European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium.

Evolving molecularly targeted therapies for advanced-stage thyroid cancers

Expression of PD-1 and PD-L1 in Anaplastic Thyroid Cancer Patients Treated With Multimodal Therapy: Results From a Retrospective Study

External beam radiation therapy for advanced/unresectable malignant paraganglioma and pheochromocytoma.

Flavopiridol binds to duplex DNA.

Flavopiridol disrupts STAT3/DNA interactions, attenuates STAT3-directed transcription, and combines with the Jak kinase inhibitor AG490 to achieve cytotoxic synergy

Flavopiridol in patients with relapsed or refractory multiple myeloma: a phase 2 trial with clinical and pharmacodynamic end-points.

Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells

Foundation OneTM Genomic Interrogation of Thyroid Cancers in Patients with Metastatic Disease Requiring Systemic Therapy

Individualization of therapies for patients with advanced differentiated thyroid cancers

Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity.

Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma

Leveraging the immune system to treat advanced thyroid cancers

Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer.

Management of treatment-related toxicities in advanced medullary thyroid cancer.

Mutated BRAF and personalised medicine in differentiated thyroid cancer.

New drugs for medullary thyroid cancer: new promises?

OPTIMIZING LENVATINIB THERAPY IN PATIENTS WITH METASTATIC RADIOACTIVE IODINE-RESISTANT DIFFERENTIATED THYROID CANCERS.

Operative intervention for recurrent adrenocortical cancer

Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer

Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies.

Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points.

Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias

Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma.

Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib.

Promises and Perils of Molecularly Targeted Therapeutics in Anaplastic Thyroid Cancer

Prosurvival function of the granulin-epithelin precursor is important in tumor progression and chemoresponse

Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer

Salvage Therapy With Multikinase Inhibitors and Immunotherapy in Advanced Adrenal Cortical Carcinoma

Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity

Surgical Treatment of Malignant Pheochromocytoma and Paraganglioma: Retrospective Case Series

Surgical resection of synchronously metastatic adrenocortical cancer

Survival in Response to Multimodal Therapy in Anaplastic Thyroid Cancer

Systemic therapeutic approaches to advanced thyroid cancers.

Taking stock of therapeutic progress in metastatic radioactive iodine-refractory differentiated thyroid cancer: what's next?

The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux

The Nitric Acid Method for Protein Estimation in Biological Samples

The Nitric Acid Method for Protein Estimation in Biological Samples

The anticancer agent chaetocin is a competitive substrate and inhibitor of thioredoxin reductase

Toward improved outcomes in patients with anaplastic thyroid cancer.

Toward predictive biomarkers of response to kinase inhibitor therapies in differentiated thyroid cancer

Toward predictive biomarkers of response to kinase inhibitor therapies in differentiated thyroid cancer

Treating advanced radioresistant differentiated thyroid cancer